Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 25, 2014
SALT LAKE CITY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
-
Nov 17, 2014
SALT LAKE CITY, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the...
-
Nov 10, 2014
SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as...
-
Oct 13, 2014Single daily oral dose provides testosterone levels in the eugonadal range
SALT LAKE CITY, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced positive top-line results from a Phase 2a clinical study of LPCN...
-
Sep 24, 2014Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects
SALT LAKE CITY, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced positive top-line efficacy results from its ongoing Study of...
-
Sep 23, 2014Conference Call and Webcast Scheduled for 8:45 a.m. Eastern Time Tomorrow
SALT LAKE CITY, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast...
-
Sep 8, 2014
SALT LAKE CITY, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the first patient was dosed in a Phase 1 study in pregnant women...
-
Aug 13, 2014
SALT LAKE CITY, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2014, as well as...
-
Jul 15, 2014
SALT LAKE CITY, July 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has...
-
Jun 30, 2014
SALT LAKE CITY, June 30, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it was added to the Russell Microcap Index when Russell...
-
May 29, 2014
SALT LAKE CITY, May 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown,...
-
May 27, 2014
SALT LAKE CITY, May 27, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in a Phase 2a clinical study...
-
May 13, 2014
SALT LAKE CITY, May 13, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, announced today announced financial results for the quarter ended March 31, 2014,...
-
Apr 29, 2014Top-line Efficacy Data Expected in 3Q14
SALT LAKE CITY, April 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company has completed enrollment of its Study of Oral...
-
Apr 15, 2014Significant absorption upon oral dosing of LPCN 1107
SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the successful completion of a Phase 1 study of LPCN 1107, the...
-
Mar 18, 2014
SALT LAKE CITY, March 18, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list...
-
Mar 5, 2014
SALT LAKE CITY, March 5, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
-
Feb 10, 2014
SALT LAKE CITY, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Study of Oral...
-
Feb 4, 2014
SALT LAKE CITY, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
-
Jan 7, 2014
SALT LAKE CITY, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced changes to the Company's Board of Directors, including...
-
Dec 13, 2013
SALT LAKE CITY, Dec. 13, 2013 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN) (OTCBB:LPCN), a specialty pharmaceutical company, today announced that Dr. William I. Higuchi will receive an honorary...
-
Dec 6, 2013
SALT LAKE CITY, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that the underwriters of its previously announced public offering...
-
Nov 27, 2013
SALT LAKE CITY, UT (GLOBENEWSWIRE) - November 27, 2013 - Lipocine Inc. ("Lipocine") (OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, today announced the pricing of an underwritten public...
-
Sep 16, 2013
SALT LAKE CITY (BUSINESS WIRE - September 16, 2013) Lipocine Inc. ("Lipocine") (OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, announced today that Morgan Brown has joined the Company as...
-
Aug 22, 2013
SALT LAKE CITY (BUSINESS WIRE - August 22, 2013) Lipocine Inc.(OTCQB⁄OTCBB:LPCN), a specialty pharmaceutical company, announced today that it has changed its trading symbol from OTCBB:MBARD to...